Clinical Trials Search
A Phase II Trial of Preoperative Paclitaxel and Carboplatin in Patients with Resectable Non-Small Cell Lung Cancer
95-24-51
- Eligibility:Click Here to View1.0) Path (+) NSCLC, T1-3, N0-1, MO (hilar node =1.5 cm on CT considered N1 dz)
2.0) Mediastinoscopy required to exclude N2 dz. See protocol
3.0) No serious cardiac problems.
4.0)
5.0) No prior chemo or RT.
6.0)
Drug: Carbo, Taxol (provided) - Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.
A Phase II Trial of Edatrexate in Combination With Vinblastine, Adriamycin, Cisplatin, and Filgrastim (EVAC/G-CSF) in Patients With Advanced Non-Small Cell Lung Cancer
95-24-52
- Eligibility:Click Here to View
- Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.
Phase III Controlled Evaluation of Glutamine for Decreasing Stomatitis in Patients Receiving 5FU (Fluorouracil) - Based Chemotherapy
95-92-51
- Eligibility:Click Here to View
- Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.
A Phase III Trial of Total Androgen Suppression Versus Total Androgen Suppression Plus Definitive External Beam Irradiation for Pathologic Lymph Node Positive (pN+) Adenocarcinoma of the Prostate
96-08
- Eligibility:Click Here to View1.0) Path (+) prostate ca with elevated PSA.
2.0) Path (+) pelvic lymph node involvement.
3.0) No prior chemo or RT.
4.0) No distant mets.
5.0) PSA = 4.0 is mandatory.
6.0) PS = 70 (0-1)
7.0) Orchiectomy if done, must be = 90 days prior to randomization; chemical hormones may be started prior to random. But must begin = 90 days before study entry.
8.0) Negative bone scan and CXR.
Drugs: Zoladex, Lupron Depot, Flutamide - Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.
A Phase II Study of Extended Field Radiation Following Therapeutic Para-aortic node Dissection for patients with carcinoma of the Uterine Cervix with Para-aortic Nodal Metastases
96-13
- Eligibility:Click Here to View1.0) No mets outside pelvis except para-aortic mets
2.0) PS = 70
3.0) No prior RT, Chemo, or hysterectomy - Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.
A Intermittent, Alternating Chemohormonotherapy Combined with Strontium-89 for Androgen Resistant Metastatic Prostate Carcinoma
96-2
- Eligibility:Click Here to View1.0) Path (+)prostate ca w/ clinical evidence of mets.
2.0) Evidence of hormone unresponsiveness/progres dz despite recent discont. of antiandrogen therapy.
3.0) If no evidence of bi-dimensional msble dz, then PSA must be >20
4.0)
5.0) PS 0-3
6.0) No prior chemo
7.0) Contraindication = 25% RT
Drug: Estramustine, Vinblastine, Adriamycin, Ketoconazole, Strontium-89 - Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.
A Phase II Study of LU 103793 in the Treatment of Advanced Non-Small Cell Lung Cancer
96-24-51
- Eligibility:Click Here to View1.0) Path (+) NSCLC with bidimensionally measurable dz.
2.0) Stage IIIB or IV NSCLC.
3.0) Arm A - No prior chemo for this dz allowed.
Arm B - Must have received only one previous chemo regimen for this dz and must have ended =4 weeks prior to study entry
4.0) PS 0-2
5.0) Cannot have: RT to >15% of bone marrow/RT =3 weeks.
6.0) Cannot have: CNS mets.
Drugs: LU 103793 (provided).
7.0) - Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.
A Phase II Trial of Oral Etoposide with Intravenous Paclitaxel in Patients with Refractory Metastatic Breast Cancer
96-32-54
- Eligibility:Click Here to View1.0) Path (+) breast ca w/evidence of met dz
2.0) must have had 1-2 prior chemo regimens
3.0) must have had 1 tx for met dz
4.0) No prior taxol or taxotere - Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.
A Phase II Trial of Irinotecan (CPT-11) in Patients with Refractory Metastatic Breast Cancer
96-32-55
- Eligibility:Click Here to View1.0) path (+)breast ca with evidence of progression
2.0) must have had 1 prior regimen in adjuvant setting and only 1 in metastatic setting
3.0) at least 1 prior regimen contained anthracycline or Taxane or Adria for either adjuvant or metastatic dz
4.0) life expectancy >3months - Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.
A Phase II Trial of Irinotecan in Recurrent Glioma
96-72-51
- Eligibility:Click Here to View1.0) Path (+)
2.0) Allowed 1 prior chemo for adj, and 1 for recurrance.
3.0) = 8 wks post RT
4.0) = 4 wks post chemo, = 6wks post nitrosourea-based chemo
Drug: CPT-11, provided.
5.0) - Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.